Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05175885

Ex Vivo Normothermic Perfusion in Kidney Transplantation.

Led by Ebers Medical Technology, S.L. · Updated on 2024-11-12

100

Participants Needed

1

Research Sites

206 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A multicenter, prospective and open-label clinical investigation to evaluate the viability, performance and safety of ex vivo normothermic perfusion in kidney transplantation from DCD and DBD donors.

CONDITIONS

Official Title

Ex Vivo Normothermic Perfusion in Kidney Transplantation.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 18 years and older
  • Patients undergoing dialysis and listed for kidney transplantation
  • Candidates for first or second kidney transplant from controlled DCD donors or DBD donors aged 70 years or older
  • Patients who provide written informed consent or have legal guardian approval if mentally compromised
  • Patients able to comply with study requirements for 1 year
  • Patients meeting clinical site criteria for kidney transplant recipients according to usual practice
Not Eligible

You will not qualify if you...

  • Two or more previous kidney transplantations
  • Dual kidney or multivisceral transplantation (e.g., pancreas-kidney)
  • Expected cold ischemia time before EVNP greater than 20 hours
  • Organs from hepatitis B surface antigen-positive or hepatitis C viremic donors
  • Organs with multiple arteries
  • Recipients with BMI over 40 kg/m2
  • Diagnosis of focal segmental glomerulosclerosis or membranoproliferative glomerulonephritis with high recurrence risk
  • Diagnosis of atypical hemolytic-uremic syndrome or thrombotic microangiopathy at inclusion
  • Diagnosis of antiphospholipid syndrome at inclusion
  • Panel-reactive antibodies (PRA) score over 50%
  • Known allergies to perfusate components
  • Preexisting vascular disease posing exceptional transplant difficulty
  • Presence of clinically relevant donor-specific anti-HLA antibodies
  • ABO blood group incompatibility
  • History of alcohol or drug abuse in last two years
  • Use of normothermic regional perfusion during organ harvesting
  • Participation in another clinical trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Miguel Servet University Hospital

Zaragoza, Spain

Actively Recruiting

Loading map...

Research Team

P

Pedro Moreo Calvo, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Ex Vivo Normothermic Perfusion in Kidney Transplantation. | DecenTrialz